Head & Neck Cancer Clinical Trial Management
Head and neck cancer trials face unique recruitment and retention hurdles. Ergomed’s patient-centric approach provides the supportive care infrastructure needed to keep patients enrolled. We bring experience in immunotherapy and combination modalities to ensure your study runs smoothly across global sites.
Trusted Partner for Complex Oncology Studies
Our extensive network of Key Opinion Leaders (KOLs) across critical regions empowers us to develop robust strategies and deliver impactful trial outcomes. Our experience spans Early Phase I (FIH), Phase I/II, Phase II, and large Phase III trials in head and neck squamous cell carcinoma (HNSCC), conducted across the US, Europe, and Asia. In the past year alone, we have managed seven head and neck cancer trials, five of which are still ongoing.
Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma study
See how Ergomed successfully advanced a first-in-human Phase I/II trial in recurrent/metastatic HNSCC, overcoming complex eligibility and tight timelines. Through KOL engagement, adaptive cohort management, and proactive safety oversight, the study achieved key milestones ahead of schedule—demonstrating Ergomed’s ability to deliver complex oncology trials with speed and precision.
Locally Advanced (LA) Squamous Cell Head and Neck Carcinoma study
Discover how Ergomed turned around one of the world’s largest head and neck cancer trials, boosting enrollment by 560% and quadrupling site performance across 120+ sites globally. Learn how our Site Support Model and intensive physician engagement helped rescue this pivotal Phase III study and deliver results showcased at ASCO, ESMO, and other leading congresses.
Global Oncology Expertise at a Glance
Ergomed has delivered over 500 oncology studies globally, including early-phase solid tumor trials, gene and cell therapy projects, and radiopharmaceutical studies. Our end-to-end services support complex designs, tight timelines, and challenging patient populations. We bring this experience into every head and neck trial—ensuring operational excellence and true therapeutic insight.
Delivering Results in Complex Head and Neck Cancer Trials:
- Proven ability to manage complex oncology trials at every phase and disease stage
- Expertise in handling challenging indications with tailored operational solutions
- Global reach with successful trial execution in diverse geographies
- Commitment to patient centricity—collaborating closely with patient engagement teams and partners like the Head and Neck Cancer Alliance
- Focus on supportive care addressing the psychological and social needs of patients and caregivers
Patient-First Commitment
We recognize that head and neck cancer profoundly affects patients and their families—not only physically but also psychologically and socially. Ergomed integrates a comprehensive patient-centric approach, working closely with advocacy groups such as the Head and Neck Cancer Alliance, and embedding supportive care strategies that improve retention and outcomes.
For Ergomed, patient centricity is not a box to tick—it is the foundation of how we deliver oncology trials. Every protocol, every site interaction, and every trial milestone is shaped by one simple philosophy: better trials mean better care for patients.
Why Partner with Ergomed for Head and Neck Oncology Trials
Choosing the right CRO is critical when navigating the complexities of head and neck oncology research. Ergomed brings together global scale, deep therapeutic expertise, and a patient-first mindset to deliver outcomes that matter—to sponsors, investigators, and patients alike.
Global Oncology Depth
With more than 500 oncology trials delivered worldwide, Ergomed combines the experience of managing early-phase solid tumor studies, gene and cell therapy projects, and radiopharmaceutical research. This breadth of expertise ensures that sponsors benefit from proven methodologies tailored to both rare populations and large-scale pivotal trials.
Influential KOL Network
Our close relationships with Key Opinion Leaders across North America, Europe, APAC, and MENA provide not only recruitment advantages but also critical input into trial design and protocol development. These collaborations enhance trial credibility, speed, and alignment with evolving standards of care.
Adaptive Trial Management
Head and neck oncology studies demand seamless coordination across multiple disciplines. Ergomed integrates site teams—including surgery, oncology, pathology, radiotherapy, and radiology—into a unified operational framework, ensuring protocol adherence, efficiency, and reduced site burden.
Recognized Thought Leadership
Ergomed is a visible voice in the global oncology community, with study results presented at leading congresses such as ASCO, ESMO, ECHNO, ESTRO, and AHNS. This presence reinforces our role as a trusted partner advancing both science and clinical practice in head and neck oncology.
Accelerate Your Head and Neck Cancer Trial with Confidence
Launching or rescuing a head and neck oncology trial requires a partner who understands the science, the patients, and the operational complexities of this therapeutic area. Ergomed brings together deep oncology knowledge, global reach, and a proven patient-first philosophy to help sponsors overcome enrollment challenges, navigate complex protocols, and deliver results that stand up to regulatory and scientific scrutiny.